Abstract:Background: With the emergence of microglia-modulating therapies there is an urgent need for reliable biomarkers to evaluate microglial activation states. Methods: Using mouse models and human induced pluripotent stem cell-derived microglia (hiMGL), genetically modified to yield the most opposite homeostatic (TREM2-knockout) and disease-associated (GRN-knockout) states, we identified microglia activity-dependent markers. Non-targeted mass spectrometry was used to identify proteomic changes in microglia and cerebrospinal fluid (CSF) of Grn- and Trem2-knockout mice. Additionally, we analyzed the proteome of GRN- and TREM2-knockout hiMGL and their conditioned media. Candidate marker proteins were tested in two independent patient cohorts, the ALLFTD cohort (GRN mutation carriers versus non-carriers), as well as the proteomic data set available from the EMIF-AD MBD study. Results: We identified proteomic changes between the opposite activation states in mouse microglia and CSF, as well as in hiMGL cell lysates and conditioned media. For further verification, we analyzed the CSF proteome of heterozygous GRN mutation carriers suffering from frontotemporal dementia (FTD). We identified a panel of six proteins (FABP3, MDH1, GDI1, CAPG, CD44, GPNMB) as potential indicators for microglial activation. Moreover, we confirmed three of these proteins (FABP3, GDI1, MDH1) to be significantly elevated in the CSF of Alzheimer's (AD) patients. Remarkably, each of these markers differentiated amyloid-positive cases with mild cognitive impairment (MCI) from amyloid-negative individuals. Conclusions: The identified candidate proteins reflect microglia activity and may be relevant for monitoring the microglial response in clinical practice and clinical trials modulating microglial activity and amyloid deposition. Moreover, the finding that three of these markers differentiate amyloid-positive from amyloid-negative MCI cases in the AD cohort suggests that these proteins associate with a very early immune response to seeded amyloid. This is consistent with our previous findings in the Dominantly Inherited Alzheimer's Disease Network (DIAN) cohort, where soluble TREM2 increases as early as 21 years before symptom onset. Moreover, in mouse models for amyloidogenesis, seeding of amyloid is limited by physiologically active microglia further supporting their early protective role. The biological functions of some of our main candidates (FABP3, CD44, GPNMB) also further emphasize that lipid dysmetabolism may be a common feature of neurodegenerative disorders.

Primate cerebrospinal fluid CHI3L1 reflects brain TREM2 agonism

Identification and Validation of TREM2 in Intracranial Aneurysms

Neutral or Detrimental Effects of TREM2 Agonist Antibodies in Preclinical Models of Alzheimers Disease and Multiple Sclerosis

TREM2 Activation Attenuates Neuroinflammation and Neuronal Apoptosis Via PI3K/Akt Pathway after Intracerebral Hemorrhage in Mice.

Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region

Proteo-genomics of soluble TREM2 in cerebrospinal fluid provides novel insights and identifies novel modulators for Alzheimer’s disease

A TREM2-activating antibody with a blood–brain barrier transport vehicle enhances microglial metabolism in Alzheimer’s disease models

Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer’s disease model

TREM2 expression level is critical for microglial state, metabolic capacity and efficacy of TREM2 agonism

O4‐02‐01: SOLUBLE TREM2 MODULATES MICROGLIAL FUNCTION AND PROTECTS AGAINST AMYLOID PATHOLOGY

Soluble TREM2 Induces Inflammatory Responses and Enhances Microglial Survival

Identification of the Minimal Active Soluble TREM2 Sequence for Modulating Microglial Phenotypes and Amyloid Pathology

Elevating Microglia TREM2 Reduces Amyloid Seeding and Suppresses Disease-Associated Microglia

A microglial activity state biomarker panel differentiates FTD-granulin and Alzheimer's disease patients from controls

The cerebrospinal fluid soluble TREM‐1 concentration in Alzheimer’s Disease (AD) and Mild Cognitive Impairment (MCI)

Gene expression and functional deficits underlie TREM2-knockout microglia responses in human models of Alzheimer’s disease

Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer’s disease model

Soluble Triggering Receptor Expressed on Myeloid Cells 2 From Cerebrospinal Fluid in Sleep Disorders Related to Parkinson’s Disease

TREM2 Regulates Microglial Cholesterol Metabolism Upon Chronic Phagocytic Challenge

TREM2 Expression and Amyloid-Beta Phagocytosis in Alzheimer’s Disease

Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease